Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism Akt-1 inhibitors(Serine/threonine-protein kinase AKT inhibitors), RSK inhibitors(Ribosomal protein S6 kinase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Drug Highest PhaseDiscontinuedPhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Hodgkin Lymphoma | Phase 3 | FR | 01 Sep 2013 | |
Solid tumor | Phase 3 | FR | 01 Sep 2013 | |
Neoplasm Metastasis | Phase 3 | ES | 01 Mar 2010 | |
Metastatic breast cancer | Phase 2 | FR | 01 Jan 2014 | |
Locally advanced breast cancer | Preclinical | FR | 01 Jan 2014 |
Phase 2 | HER2-negative breast cancer HER2-negative | PI3K/AKT pathway | 51 | (oelsyaliuc) = unlyfwszao qomyhvqnuc (kinpkdltvo, 48.8 - 76.8) | - | 01 Dec 2021 | ||
Phase 2 | 35 | LY2780301 + wP | (gvypmzxifj) = 50% of pts, G3-4 in 8% fclkdqytyf (fnjwhxtkek ) View more | Positive | 26 May 2019 | ||
Phase 1 | 50 | LY2780301+gemcitabine | (fozgokviqz) = anaemia (84%), fatigue (84%), transaminase increase (74%), thrombocytopenia (74%), nausea/vomiting (70%), neutropenia (68%) and lymphopenia (56%) zowxnmldjm (esnvimiikd ) View more | Positive | 01 Sep 2017 | ||
Phase 1 | 32 | (qqaaeekydm) = mpyfblgbrd yuhhyasmfr (dxvlrqcfsa ) View more | Positive | 01 Jun 2015 | |||
Phase 1 | 32 | (ffsxmwamzg) = prolonged stable disease for 6.5 cycles cfrhalshva (plbvvvadoc ) View more | - | 20 May 2012 |